ENB Therapeutics
  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us
Select Page

ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors

by admin | Feb 4, 2019 | Press Releases

New York, NY., February 4th, 2019 — ENB Therapeutics, Inc., a clinical-stage, biopharmaceutical company developing innovative, endothelin-based oncologics, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD...

Recent Posts

  • ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
  • ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer
  • ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab
  • Early efficacy signals in ovarian cancer patients in ongoing Ph1 trial: Poster reporting findings presented at SITC 2020 Annual Meeting
  • ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase 1 Clinical Trial of ENB-003 in Combination with Pembrolizumab

Archives

  • November 2022
  • May 2022
  • February 2021
  • November 2020
  • February 2019
  • September 2018
  • April 2016
  • January 2016
  • June 2015

Categories

  • Press Releases
  • Uncategorized

Explore

  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us

Recent Posts

Click Here

ENB Therapeutics
Alexandria Center For Life Sciences,
Launch Labs
430 E 29th Street, 14th Floor
New York, NY 10016
(212) 792-2317
info@enbpharma.com

Designed by Elegant Themes | Powered by WordPress